Brainstorm Cell Therapeutics Company Profile

05:25 EDT 23rd March 2018 | BioPortfolio

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to treat diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) and Multiple Sclerosis (MS). The adult stem cells are used to create healthy new brain-like cells that replace or support the diseased cells. Patients treated with the Company’s NurOwn™ therapeutic cells are expected to enjoy a rapid recovery and much enhanced quality of life. BrainStorm's therapy has the potential to cure underlying pathology, rather than simply treat symptoms. BrainStorm's management and scientific teams are passionately devoted to the Company's mission: regenerating the mind... in their lifetime.


110 East 59th Street
New York
United States of America


Phone: (212)-557-9000
Fax: (212)-581-8958

News Articles [2151 Associated News Articles listed on BioPortfolio]

VIDEO: BrainStorm Cell Therapeutics Seeks JVs And Investors To Commercialize Stem Cell Pipeline

Chaim Lebovits, president and CEO of BrainStorm Cell Therapeutics, discusses the company's stem cell trials in ALS and other ventures...   

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV (Reuters) - BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hos...

BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold ...

HACKENSACK, N.J.and PETACH TIKVAH, Israel, March 12, 2018/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem Read more...

Brainstorm Cell Therapeutics (BCLI) Presents At 10th Annual Biotech Showcase 2018 - Slideshow

BrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q4 2017 Results - Earnings Call Transcript

BrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q3 2017 Results - Earnings Call Transcript

Takeda Catches Rising Tide Of Antisense Neuroscience R&D

Huntington's disease is one of several genetically defined neurological diseases that are being targeted in a multibillion-dollar collaboration forged between...   

Preparing Emerging Biotechs For The Best Deals – Insider Insights

As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing...   

PubMed Articles [3315 Associated PubMed Articles listed on BioPortfolio]

Developing T-cell therapies for lymphoma without receptor engineering.

T-cell therapy has emerged from the bench for the treatment of patients with lymphoma. Responses to T-cell therapeutics are regulated by multiple factors, including the patient's immune system status ...

Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver.

Oligonucleotide therapeutics have emerged as a third distinct platform for drug discovery within the pharmaceutical industry. Five oligonucleotide-based drugs have been approved by the US FDA and over...

Cancer Cell Controller.

Cancer is the disease which exists when the cell is uncontrolled. This paper presents a controller for the same. The cancer cell is reviewed via algebraic structures.

Non-protein biologic therapeutics.

While the therapeutic biologics are dominated by therapeutic proteins, particularly monoclonal antibodies, a wide range of non-protein therapeutic biologics are rapidly gaining ground both in clinical...

Regenerative Rehabilitation: Applied Biophysics Meets Stem Cell Therapeutics.

The emerging field of regenerative rehabilitation integrates biological and bioengineering advances in regenerative medicine with rehabilitative sciences. Here we highlight recent stem cell-based exam...

Clinical Trials [5832 Associated Clinical Trials listed on BioPortfolio]

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease

This study evaluates the safety and clinical benefits of a therapeutics approach of conditioning regimen Cyclophosphamide (Cy) + Thymoglobulin r (ATG) + Granulocyte Colony-Stimulating Fact...

Companies [2073 Associated Companies listed on BioPortfolio]

BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a promising company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of ne...

Brainstorm Cell Therapeutics

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult st...

BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of ne...

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based dise...

Opsis Therapeutics

Opsis Therapeutics is a company focused on discovering and developing new medicines to restore vision to patients suffering from retinal diseases. By combining recent innovations ...

More Information about "Brainstorm Cell Therapeutics" on BioPortfolio

We have published hundreds of Brainstorm Cell Therapeutics news stories on BioPortfolio along with dozens of Brainstorm Cell Therapeutics Clinical Trials and PubMed Articles about Brainstorm Cell Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Brainstorm Cell Therapeutics Companies in our database. You can also find out about relevant Brainstorm Cell Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Corporate Database Quicklinks

Searches Linking to this Company Record